格隆汇12月1日丨银诺医药-B(02591.HK)宣布，于2025年12月1日，公司及银诺技术(公司一间直接全资 附属公司)以代价合共人民币1.25亿元(即其总本金额)分别向宁波银行认购一款结构性存款产品(即宁波 银行结构性存款产品)。 ...

银诺医药-B(02591)公布，于2025年12月1日，公司及银诺技术(公司一间直接全资附属公司)以代价合共 人民币1.25亿元(即其总本金额)分别向宁波银行认购一款结构性存款产品(即宁波银行结构性存款产 品)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 有關認購結構性存款產品的須予披露交易 董事會宣佈，於2025年12月1日，本公司及銀諾技術（本公司一間直接全資附屬公 司）以代價合共人民幣125,000,000元（即其總本金額）分別向寧波銀行認購一款結 構性存款產品（即寧波銀行結構性存款產品）。 本公司及銀諾技術各自認購寧波銀行結構性存款產品的主要條款載列如下： | 認購方 | 產品名稱 | 本金額 | 認購日期 | 生效日期 | 到期日 | 預期年化回報率 | | --- | --- | --- | --- | --- | --- | --- | | 本公司 | 寧波銀行結構性 | 人民幣 | 2025年12月1日 | 2025年12月3日 | 2025年12月3 ...

Group 1 - Silver诺医药-B (02591.HK) shares increased nearly 7% in a single trading day [2] - Over the past four trading days, the stock price has surged over 50% [2] - As of the latest update, the stock is trading at 44.68 HKD with a transaction volume of 35.366 million HKD [2]

智通财经APP获悉，银诺医药-B(02591)再涨近7%，四个交易日股价累计涨超50%。截至发稿，涨 6.79%，报44.68港元，成交额3536.66万港元。 据悉，银诺医药是一家专注于代谢性疾病领域的生物医药公司，目前拥有多项针对糖尿病、肥胖和非酒 精性脂肪性肝炎等适应症的创新药物研发管线，全部为自主研发，具备全球知识产权，覆盖全球研发与 市场布局。 消息面上，11月21日，恒生指数系列季度检讨结果出炉，其中，银诺医药获纳入恒生综合指数成份股， 变动将于2025年12月8日起生效。据中金预测，银诺医药等符合港股通纳入范围。 ...

银诺医药-B(02591)再涨超6%，昨日股价飙涨超30%。截至发稿，涨6.11%，报40.3港元，成交额2313.13 万港元。 消息面上，11月21日，恒生指数系列季度检讨结果出炉，所有变动将于2025年12月8日起生效。其中， 银诺医药获纳入恒生综合指数成份股。上海证券此前研报指出，银诺医药依苏帕格鲁肽α具有良好的安 全性和降糖、减重效果，在治疗糖尿病、肥胖、脂肪肝等慢性代谢性疾病方面表现显著优势，公司登陆 港交所有望推进研发管线及商业化拓展。 ...

每经AI快讯，银诺医药-B(02591.HK)涨超6%，昨日股价飙涨超30%。截至发稿，涨6.11%，报40.3港 元，成交额2313.13万港元。 ...

Core Viewpoint - The expectation for a rate cut by the Federal Reserve in December has increased, leading to a rise in Hong Kong stock indices, with the Hang Seng Index closing up 1.97% at 25,716.5 points, and a total trading volume of 302.64 billion HKD [1] Group 1: Market Performance - The three major indices in Hong Kong collectively rose, with the Hang Seng Index gaining over 2% at one point during the day [1] - The Hang Seng Technology Index increased by 2.78%, closing at 5,545.56 points [1] - The trading volume for the day reached 302.64 billion HKD [1] Group 2: Blue-Chip Stocks - Alibaba-W (09988) saw a significant increase of 4.67%, closing at 154.5 HKD, contributing 104.44 points to the Hang Seng Index [2] - Kuaishou-W (01024) rose by 7.11%, while NetEase-S (09999) increased by 5.87%, contributing 21.51 points and 26.03 points to the index respectively [2] Group 3: Sector Performance - Technology stocks rebounded, with Kuaishou rising over 7% and NetEase nearly 6% [3] - AI applications are gaining traction, with notable increases in stocks related to AI, such as Chuangmeng Tiandi (01119) up 9.38% and Innovation Qizhi (02121) up 8.83% [3] - Military stocks performed strongly, with China Shipbuilding Defense (00317) rising by 13.07% [4] Group 4: Automotive Sector - The automotive sector saw widespread gains, with GAC Group (02238) increasing by 12.03% and Beijing Automotive (01958) rising by 5.91% [5] - The Guangzhou Auto Show featured 93 new car launches, with nearly 60% being new energy vehicles [6] Group 5: Lithium and Semiconductor Stocks - Lithium stocks continued to decline, with Ganfeng Lithium (01772) down 5.66% [7] - Semiconductor stocks showed weakness, with Hua Hong Semiconductor (01347) falling by 4.91% [7] Group 6: Notable Stock Movements - Innovation Industry (02788) debuted with a significant increase of 32.76%, closing at 14.59 HKD [9] - Silver诺医药-B (02591) surged by 31.15% after being included in the Hang Seng Composite Index [10] - Miniso (09896) faced pressure post-earnings, with a decline of 4.84% despite a revenue increase of 28.2% [11]

Core Viewpoint - Silver诺医药-B (02591) has seen a nearly 10% increase in stock price following its inclusion in the Hang Seng Composite Index, effective December 8, 2025, which is expected to enhance its market visibility and support its research and commercialization efforts [1] Group 1: Stock Performance - As of the report, Silver诺医药-B's stock price rose by 9.81%, reaching 31.8 HKD, with a trading volume of 2.7693 million HKD [1] Group 2: Clinical Trials and Product Development - On November 21, it was announced that Silver诺医药 has completed the first patient dosing in a Phase III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight conditions, with plans to recruit approximately 800 participants [1] - The company has demonstrated that Isuparaglutide α has good safety profiles and significant effects in reducing blood sugar and weight, showing advantages in treating chronic metabolic diseases such as diabetes, obesity, and fatty liver [1] Group 3: Market Outlook and Competition - The GLP-1 sector remains a focus, with ongoing competition intensifying; stakeholders are advised to monitor the expansion of indications, submission for market approval, and the commercialization process [1]

Group 1 - Hong Kong's Hang Seng Index rose by 1.42%, gaining 358 points to close at 25,578 points, while the Hang Seng Tech Index increased by 1.65% [1] - Alibaba-W (09988) surged over 4%, with its Qianwen App surpassing 10 million downloads in its first week of public testing [1] - Sinopharm (01801) rose over 3%, with plans to officially go blue starting December 8 [1] - Hengrui Medicine (01276) increased by over 5%, as nine drugs including SHR-9839 received approval for clinical trials [1] - Beijing Automotive (01958) gained over 3%, planning to sell 51% of its stake in Beiqi International for approximately 1.608 billion yuan to accelerate its international strategy [1] - WeRide (00800) jumped over 6%, having obtained Switzerland's first pure driverless license, with Q3 earnings report upcoming [1] - Rusal (00486) saw an intraday increase of over 4%, announcing plans to cease operations at the Krymni silicon plant by 2026 [1] - GAC Group (02238) surged over 12%, with its all-solid-state battery pilot production line officially completed and put into production [1] - Sino Biopharmaceutical-B (02591) rose over 20%, being included in the Hang Seng Composite Index effective December 8 [1] - 3SBio (01530) increased by over 4%, planning to spin off its subsidiary Mandi International for independent listing [1] Group 2 - Oil stocks continued to decline, with CNOOC (00883) dropping by 2.4% amid easing tensions in the Russia-Ukraine situation [2] - Semiconductor stocks faced significant declines, with Hua Hong Semiconductor (01347) falling over 9% and SMIC (00981) down over 5%, as reports indicated the Trump administration is considering approving exports of Nvidia's H200 AI chips to China [2] - Ganfeng Lithium (01772) dropped over 7%, facing potential downward risks in lithium spot prices, leading Goldman Sachs to downgrade the company to a "sell" rating [2]